Alnylam Pharmaceuticals Inc. (ALNY)

68.22
0.35 0.52
NASDAQ : Health Technology
Prev Close 67.87
Open 67.58
Day Low/High 66.12 / 68.72
52 Wk Low/High 60.27 / 124.22
Volume 392.37K
Avg Volume 963.60K
Exchange NASDAQ
Shares Outstanding 106.54M
Market Cap 7.20B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Alnylam To Webcast Presentations At Upcoming November Investor Conferences

Alnylam To Webcast Presentations At Upcoming November Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 26 th Annual Credit...

Alnylam To Webcast Conference Call Discussing Third Quarter 2017 Financial Results

Alnylam To Webcast Conference Call Discussing Third Quarter 2017 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2017 on Tuesday, November 7, 2017,...

Alnylam And Collaborators To Present APOLLO Phase 3 Study Results At 1st European ATTR Amyloidosis Meeting For Patients And Doctors

Alnylam And Collaborators To Present APOLLO Phase 3 Study Results At 1st European ATTR Amyloidosis Meeting For Patients And Doctors

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the results of the APOLLO Phase 3 study of patisiran in hereditary ATTR (hATTR) amyloidosis patients with...

Alnylam And Vir Form Strategic Alliance To Advance RNAi Therapeutics For Infectious Diseases

Alnylam And Vir Form Strategic Alliance To Advance RNAi Therapeutics For Infectious Diseases

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced an exclusive licensing agreement with Vir Biotechnology, a company dedicated to transforming the care of people...

Alnylam Initiates Phase 2 Clinical Study Of Cemdisiran (ALN-CC5) In Patients With Atypical Hemolytic-Uremic Syndrome (aHUS)

Alnylam Initiates Phase 2 Clinical Study Of Cemdisiran (ALN-CC5) In Patients With Atypical Hemolytic-Uremic Syndrome (aHUS)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has initiated a Phase 2 clinical study with cemdisiran (formerly known as ALN-CC5), a subcutaneously...

Alnylam Continues Leadership In RNAi Technologies And Delivery With New Pre-Clinical Data Presented On "Enhanced Stabilization Chemistry Plus" (ESC+) GalNAc-siRNA Conjugate Platform At 13th Annual Meeting Of The Oligonucleotide Therapeutics Society

Alnylam Continues Leadership In RNAi Technologies And Delivery With New Pre-Clinical Data Presented On "Enhanced Stabilization Chemistry Plus" (ESC+) GalNAc-siRNA Conjugate Platform At 13th Annual Meeting Of The Oligonucleotide Therapeutics Society

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that the Company presented new pre-clinical data highlighting its next generation "Enhanced Stabilization Chemistry...

Alnylam Shares Skyrocket on Clinical Study Results - Biotech Movers

Alnylam Shares Skyrocket on Clinical Study Results - Biotech Movers

Alnylam and Sanofi Genzyme announced positive topline results from a Phase 3 study of patisiran, which is being developed for patients with hereditary ATTR amyloidosis with polyneuropathy.

Alnylam And Sanofi Report Positive Topline Results From APOLLO Phase 3 Study Of Patisiran In Hereditary ATTR (hATTR) Amyloidosis Patients With Polyneuropathy

Alnylam And Sanofi Report Positive Topline Results From APOLLO Phase 3 Study Of Patisiran In Hereditary ATTR (hATTR) Amyloidosis Patients With Polyneuropathy

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the APOLLO Phase 3 study of...

Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers

Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers

Standard treatments can cause motor side effects and/or weight gain, cardiovascular complications, dyslipidemia, and hyperglycemia.

Alnylam Provides Pipeline Update On Fitusiran And Givosiran Investigational RNAi Therapeutic Programs

Alnylam Provides Pipeline Update On Fitusiran And Givosiran Investigational RNAi Therapeutic Programs

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading RNAi therapeutics company, announced today an update on the company's fitusiran and givosiran investigational RNAi therapeutic programs.

Alnylam To Webcast Presentation At 15th Annual Morgan Stanley Global Healthcare Conference

Alnylam To Webcast Presentation At 15th Annual Morgan Stanley Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that management will present a company overview at the 15 th Annual Morgan Stanley Global Healthcare...

Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Second Quarter 2017 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2017, and highlighted recent progress in advancing its...

Alnylam To Webcast Conference Call Discussing Second Quarter 2017 Financial Results

Alnylam To Webcast Conference Call Discussing Second Quarter 2017 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2017 on Wednesday, August 9, 2017,...

Alnylam To Host Fourth Annual "RNAi Roundtable" Webcast Series

Alnylam To Host Fourth Annual "RNAi Roundtable" Webcast Series

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it plans to host its 4 th annual series of "RNAi Roundtable" webcasts this summer and early fall.

Tesla's Rally Has Died: Stock Falls to Sixth Worst Performer in Russell 1000

Tesla's Rally Has Died: Stock Falls to Sixth Worst Performer in Russell 1000

It was the seventh best performer in the index during the first half of the year.

Alnylam And Sanofi Genzyme Report Positive Results From Ongoing Phase 2 Open-Label Extension Study With Investigational RNAi Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors

Alnylam And Sanofi Genzyme Report Positive Results From Ongoing Phase 2 Open-Label Extension Study With Investigational RNAi Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors

Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today new positive results from the ongoing...

Alnylam And Sanofi Genzyme Initiate ATLAS Phase 3 Program With Investigational RNAi Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors

Alnylam And Sanofi Genzyme Initiate ATLAS Phase 3 Program With Investigational RNAi Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today the initiation of the ATLAS Phase 3...

Alnylam And Sanofi Genzyme To Present New Clinical Trial Results At The International Society Of Thrombosis And Haemostasis (ISTH) Congress

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced that new results from an ongoing Phase 2...

Alnylam Reports New Positive Clinical Results For Givosiran (ALN-AS1), An Investigational RNAi Therapeutic For The Treatment Of Acute Hepatic Porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today new positive interim results from Part C, cohorts 1-3, of its ongoing double-blind, randomized, placebo-controlled...

Alnylam CEO, John Maraganore, Named BIO Chair For 2017-2018 Term

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that Chief Executive Officer John Maraganore, Ph.

Alnylam Significantly Expands Patent Portfolio With New Allowances From United States Patent And Trademark Office

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for two patent...

FDA Grants Breakthrough Therapy Designation For Alnylam's Givosiran For The Prophylaxis Of Attacks In Patients With Acute Hepatic Porphyria

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has received Breakthrough Therapy designation from the U.

Alnylam To Webcast Presentation At Jefferies 2017 Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies 2017 Healthcare Conference on Tuesday, June 6, 2017 at...

Biotech Movers: Inovio, Neurocrine, Alnylam

Biotech Movers: Inovio, Neurocrine, Alnylam

Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday.

Alnylam Pharmaceuticals Prices Public Offering Of Common Stock

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of...

Alnylam Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of 5,000,000 shares of its common stock.

Biotech Movers: Ionis, Alnylam, Amicus, Minerva

Biotech Movers: Ionis, Alnylam, Amicus, Minerva

Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Amicus Therapeutics and Minerva Neurosciences were among the biotech movers in premarket trading on Monday.

Alnylam Pharmaceuticals, Inc. Reports Inducement Grant To New Chief Financial Officer

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has granted stock options to Manmeet S.

TheStreet Quant Rating: D (Sell)